Medela simplifies the delivery and management of Negative Pressure Wound Therapy (NPWT)

Published on:

MCHENRY, IL. May 30, 2017 – Medela Healthcare announces the launch of the new Invia® FitPad™ Negative Pressure Wound Therapy dressing portfolio, making NPWT easier for healthcare professionals and patients. “With the launch of this versatile portfolio of devices and dressings, Medela’s new NPWT portfolio supports easier patient transitions from hospital to home. Our NPWT solutions are designed for ease-of-use by clinicians and patients”, states Dan Hyun, Vice President Medela Healthcare US.

NPWT from Medela helps reduce the clinical and administrative complexity of therapy. Medela`s Invia® Liberty™ and Invia® Motion™ systems include a new dynamic pressure management feature which helps ensure controlled and reliable negative pressure delivery at the wound site[1]. The new FitPad suction interface enables the dynamic measurement of pressure settings from the pump to the dressing site.

Medela provides a streamlined portfolio of both foam and gauze dressings. Invia Dressing Kits are available in a full range of sizes. All FitPad kits share the same adhesive transparent film, a low-profile FitPad suction interface and a Quick-connector for secure and convenient[2] tubing attachment. Medela NPWT Patients and their Caregivers can now have confidence in their therapy from pump to wound site.

The Invia® Motion™ completes the Medela portfolio, combining the convenience of a personal use system with the performance associated with a reusable pump. Invia Motion can be used in all patient care settings and assists with patient transitions throughout the continuum of care.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.